Nektar (NKTR) Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase 2 study evaluating NKTR-255 for the treatment of radiation induced lymphopenia after concurrent chemoradiation in locally advanced non-small cell lung cancer, or NSCLC, patients at the Society for Immunotherapy of Cancer, or SITC, Annual Meeting. The results from the preplanned interim analysis from the REStoring lymphoCytes Using NKTR-255 after chemoradiothErapy in solid tumors, or RESCUE, trial suggest that NKTR-255 effectively reversed radiation induced lymphopenia in patients with locally advanced NSCLC receiving consolidation therapy with durvalumab. Interim pharmacodynamic data demonstrated statistically significant superiority of the eight-week absolute lymphocyte count with NKTR-255 post chemoradiation and in combination with durvalumab versus non-contemporaneous control groups who received either chemoradiation alone or chemoradiation in combination with durvalumab. “These results, combined with the body of evidence previously reported with NKTR-255 in combination with cell therapy, highlight NKTR-255’s potential to enhance clinical benefit in both hematologic malignancies and solid tumors” said Mary Tagliaferri, MD, Senior Vice President and Chief Medical Officer at Nektar.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NKTR:
- Biotech Alert: Searches spiking for these stocks today
- Nektar Therapeutics (NKTR) Q3 Earnings Cheat Sheet
- Roblox, Peloton upgraded: Wall Street’s top analyst calls
- Nektar Therapeutics Sells Manufacturing Facility for $90M
- Nektar to sell its Huntsville, Alabama facility to Ampersand Capital for $90M
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
